Oral AMD treatment meets phase 2 endpoints
At the American Society of Retina Specialists meeting, Michael Stewart, MD, chairman and professor of ophthalmology at the Mayo Clinic of Jacksonville, Florida, discusses phase 2 results of AKST4290 (Alkahest), an orally administered small molecule CCR3 inhibitor.
Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpoints
Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 was also found to be safe and well-tolerated, meeting the secondary endpoint of the trial.
Anthony Fiorino, MD, PhD: Using nVNS in Various Migraine Populations
At the 2019 American Headache Society Annual Meeting, July 11-14, in Philadelphia, Pennsylvania, one of the topics of focus among the newly approved therapies for migraine was the use of devices to treat the condition acutely. As such, a number of companies presented data on neuromodulation and neurostimulation devices—including electroCore, which has undergone the development of noninvasive vagus nerve stimulation (nVNS) to treat migraine, episodic cluster headache, and is currently being studied in post-traumatic headache.
Oncocyte CEO, Ronnie Andrews On Developing New Ways To Test For Lung Cancer
Watch “Ronnie Andrews On Developing New Ways To Test For Lung Cancer”, an archived episode of The Watch List originally aired 07/15/2019 on the TD Ameritrade Network.
Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business
The Gaitherburg biotech’s CEO, not yet a year into his tenure, sees the prospect of more acquisitions or licensing deals going forward.
Positive results of a prep-free colon cancer screening device reported
Check-Cap announced positive final results from its completed post-CE approval study evaluating the efficacy and safety of the C-Scan system. “The final results from the post-CE approval study confirm the potential clinical value of the C-Scan system. The results also demonstrate an advancement in the detection of larger polyps, generally considered to have higher potential for malignant transformation,” Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center at the Tel-Aviv Sourasky Medical Center, said in a press release.
Interview with the CEO: electroCore, Inc. (NASDAQ:ECOR)
Francis R. Amato is Chief Executive Officer of electroCore, Inc. Prior to being the Chief Executive Officer and joining electroCore in 2012, Mr. Amato spent 22 years in the pharmaceutical industry, most recently at Merck, where he served as Vice President of the Specialty Commercial Operations Group within Global Human Health.
Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline
Hot on the heels of inking an international distribution deal with Terumo, Orchestra BioMed has secured $34 million in new funding for its devices aimed at high blood pressure and blocked arteries. The series B-1 raise, and its previous series B round, also provide for follow-on investments of up to $57 million in the company. The latest preferred stock financing was led by Perceptive Advisors, RTW Investments and Soleus Capital, alongside additional backing from Terumo and previous investor SternAegis Ventures.
